Glembatumumab vedotin Withdrawn Phase 0 Trials for Triple Negative Breast Cancer (TNBC) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT03473691Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer